Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBMG Cellular Biomedicine Group		$19.68	$11.48 ▼ $19.75	$384.69M	1.35	129,776 shs	8,375 shs
IOVA Iovance Biotherapeutics	$2.08 -7.1%	$2.55	$1.64 ▼ $12.51	$694.58M	0.86	11.77 million shs	12.60 million shs
LENZ LENZ Therapeutics	$28.82 -0.6%	$26.94	$16.28 ▼ $38.93	$811.17M	0.42	190,857 shs	186,647 shs
NVAX Novavax	$7.03 +1.3%	$6.71	$5.01 ▼ $17.81	$1.14B	2.8	6.52 million shs	4.58 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBMG Cellular Biomedicine Group	0.00%	0.00%	0.00%	0.00%	0.00%
IOVA Iovance Biotherapeutics	0.00%	+9.27%	+34.94%	-40.11%	-72.55%
LENZ LENZ Therapeutics	0.00%	-9.26%	+8.17%	+22.93%	+56.42%
NVAX Novavax	0.00%	-6.85%	+3.12%	-17.18%	-51.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBMG Cellular Biomedicine Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	4.6513 of 5 stars	4.3	1.0	0.0	4.2	2.2	4.2	1.3
LENZ LENZ Therapeutics	1.5084 of 5 stars	3.6	1.0	0.0	0.0	2.2	0.8	0.0
NVAX Novavax	3.8823 of 5 stars	3.3	2.0	0.0	4.7	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBMG Cellular Biomedicine Group	0.00	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$13.30	539.42% Upside
LENZ LENZ Therapeutics	3.17	Buy	$46.60	61.69% Upside
NVAX Novavax	2.50	Moderate Buy	$19.20	173.12% Upside

Current Analyst Ratings Breakdown

Latest CBMG, NVAX, IOVA, and LENZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00
5/12/2025	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $10.00
5/12/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/12/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
5/9/2025	IOVA Iovance Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $20.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBMG Cellular Biomedicine Group	$340K	0.00	N/A	N/A	$2.89 per share	0.00
IOVA Iovance Biotherapeutics	$212.68M	3.27	N/A	N/A	$2.28 per share	0.91
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$22.06 per share	N/A
NVAX Novavax	$1.21B	0.94	N/A	N/A	($6.04) per share	-1.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBMG Cellular Biomedicine Group	-$49.98M	N/A	N/A	N/A	N/A	N/A	-144.80%	-61.68%	N/A
IOVA Iovance Biotherapeutics	-$444.04M	-$1.24	N/A	N/A	N/A	-451.25%	-58.43%	-45.48%	8/6/2025 (Estimated)
LENZ LENZ Therapeutics	-$124.65M	-$1.77	N/A	N/A	N/A	N/A	-58.48%	-55.50%	8/13/2025 (Estimated)
NVAX Novavax	-$545.06M	$2.65	N/A	87.88	2.85	-32.18%	N/A	-17.05%	8/14/2025 (Estimated)

Latest CBMG, NVAX, IOVA, and LENZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million
5/7/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
3/19/2025	Q4 2024	LENZ LENZ Therapeutics	-$0.42	-$0.46	-$0.04	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBMG Cellular Biomedicine Group	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBMG Cellular Biomedicine Group	N/A	0.47	0.47
IOVA Iovance Biotherapeutics	N/A	4.22	3.90
LENZ LENZ Therapeutics	N/A	28.63	28.63
NVAX Novavax	N/A	0.93	0.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBMG Cellular Biomedicine Group	21.98%
IOVA Iovance Biotherapeutics	77.03%
LENZ LENZ Therapeutics	54.32%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
CBMG Cellular Biomedicine Group	8.50%
IOVA Iovance Biotherapeutics	10.30%
LENZ LENZ Therapeutics	6.90%
NVAX Novavax	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBMG Cellular Biomedicine Group	217	19.48 million	N/A	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	267.90 million	Optionable
LENZ LENZ Therapeutics	110	28.15 million	16.94 million	N/A
NVAX Novavax	1,990	161.97 million	158.58 million	Optionable

CBMG, NVAX, IOVA, and LENZ Headlines

Recent News About These Companies

Analysts Conflicted on These Healthcare Names: Novavax (NVAX) and Intuitive Surgical (ISRG)

June 14 at 3:02 AM | theglobeandmail.com

Novavax: New Vaccine, Same Old Story - Still A Sell

June 13 at 11:52 AM | seekingalpha.com

Novavax, Inc. (NASDAQ:NVAX) Shares Sold by SG Americas Securities LLC

June 13 at 4:21 AM | marketbeat.com

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response

June 12, 2025 | zacks.com

Novavax's COVID-flu combo vaccine shows strong immune response in trial

June 12, 2025 | msn.com

Novavax preps late-stage trial as COVID-flu combo vaccine matches rivals

June 12, 2025 | thepharmaletter.com

Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

June 11, 2025 | seekingalpha.com

Novavax’s COVID-flu combo vaccine shows strong immune response

June 11, 2025 | msn.com

Tesla, Victoria’s Secret, Novavax rise premarket; Chewy, Gitlab fall

June 11, 2025 | investing.com

Novavax posts immune data to back COVID-flu combo shot and standalone flu shot

June 11, 2025 | msn.com

Novavax (NasdaqGS:NVAX) Announces Promising Results for New Vaccine Candidates

June 11, 2025 | finance.yahoo.com

Novavax’s Covid-Flu Combo, Standalone Flu Vaccines Demonstrate Robust Immune Response In Late-Stage Trial: Retail Says It’s ‘A Very Good Sign’

June 11, 2025 | msn.com

Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial

June 11, 2025 | benzinga.com

Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy?

June 11, 2025 | zacks.com

Novavax Stock (NVAX) Gets a Boost from ‘Robust Immune Responses’

June 11, 2025 | tipranks.com

Novavax Reports Promising Phase 3 Vaccine Trial Results

June 11, 2025 | tipranks.com

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study

June 11, 2025 | reuters.com

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

June 11, 2025 | prnewswire.com

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

June 10, 2025 | barrons.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.16 Million Position in Novavax, Inc. (NASDAQ:NVAX)

June 7, 2025 | marketbeat.com

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

June 6, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBMG, NVAX, IOVA, and LENZ Company Descriptions

Cellular Biomedicine Group NASDAQ:CBMG

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Iovance Biotherapeutics NASDAQ:IOVA

$2.08 -0.16 (-7.14%)

Closing price 04:00 PM Eastern

Extended Trading

$2.09 +0.01 (+0.67%)

As of 05:25 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

LENZ Therapeutics NASDAQ:LENZ

$28.82 -0.18 (-0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$28.88 +0.07 (+0.23%)

As of 04:04 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Novavax NASDAQ:NVAX

$7.03 +0.09 (+1.30%)

Closing price 04:00 PM Eastern

Extended Trading

$7.02 -0.01 (-0.14%)

As of 05:35 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time